Physicians should expect tough patient questions about niacin

03/15/2013 | MedPage Today (free registration)

Patients are asking about niacin therapy in light of results from the HPS2-THRIVE study, which failed to substantiate hopes that extended-release niacin/laropiprant would reduce major vascular events. "The average patient might think, upon reading results of the THRIVE study, that the risks of niacin clearly outweigh the benefits when it comes to preventing heart disease. It's our job to explain that it's not that simple," writes Dr. Sanjay Gupta.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC